Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

home > treatment > sclc > recurrent

SCLC Treatment - Recurrent Disease

Multi-institutional Phase II Trial of Irinotecan, Cisplatin, and Etoposide for Sensitive Relapsed SCLC (PubMed)
A multi-institutional phase II study was conducted to evaluate the efficacy and toxicity of CPT-11 (irinotecan) combined with cisplatin and etoposide for the treatment of sensitive relapsed SCLC. The study concluded that this regimen is highly active and well-tolerated for the treatment of sensitive relapsed SCLC. Published in the July 27, 2004 issue of the British Journal of Cancer. [7/04]

Phase II Trial of Gemcitabine in Refractory or Relapsed SCLC (PubMed)
Summarizes the results of a Phase II trial to investigate the activity of gemcitabine in patients with relapsed SCLC. Concludes that gemcitabine has modest activity in previously treated SCLC patients with a favorable toxicity profile. Further investigation with other chemotherapy drugs or targeted biologic compounds is recommended. [4/03]

Issues in Relapsed Small Cell Lung Cancer (Medscape)
Jeffrey Crawford, MD, discusses treatment options for relapsed SCLC. This CME module is aimed at physicians. Registration required for free access to Medscape. [4/02]

Additional Chemotherapy Seen As Viable Option for Recurrent Lung Cancer (Doctor's Guide)
Summarizes updated National Comprehensive Cancer Network (NCCN) treatment algorithm for patients with recurrent SCLC. The revised guidelines are based on results of studies that indicate additional courses of chemotherapy is a viable treatment option for patients with recurrent SCLC and a good performance status. The revised guidelines list a number of anticancer agents that can be employed for treating recurrent disease. [3/01]

Combination of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support for the Treatment of Refractory or Relapsed SCLC (PublMed)
Abstract of a study reported in the August 2000 issue of Oncology that found the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly active for the treatment of refractory or relapsed SCLC. [8/00]

Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small Cell Lung Cancer (Journal of Clinical Oncology)
by Christos Kosmas et al.
v.19, no.1 JCO (January 2001): 119-126
Abstract of a study evaluating the efficacy of the paclitaxel, ifosfamide, and cisplatin (PIC) combination in relapsed SCLC. Concludes that PIC appeared highly active and tolerable in patients with relapsed SCLC when it was administered as a second-line treatment. An evaluation of the PIC regimen as front-line treatment of SCLC is planned. [1/01]


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor